Exelixis (EXEL) 10-Q2022 Q1 Quarterly report

Filed: 10 May 22, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: academia, accumulator, adjacent, Aduhelm, Advisory, advocating, Alzheimer, antigen, begun, bioavailable, bioconjugation, biotherapeutic, bond, Budget, CAMILLA, controversy, correspondingly, covalent, cyber, Damstadt, detriment, durvalumab, exempt, feet, Gastrointestinal, Goodman, head, inflationary, intolerant, Kingdom, light, linked, methodology, mismatch, molecularly, multispecific, narrowed, narrowing, NBE, neck, occurrence, Omicron, owed, paper, paradigm, plaintiff, polymorphic, potent, pre, preceding, preliminarily, rapidly, raw, reclassification, regorafenib, remitted, repair, Royal, RSU, rule, Russian, salt, satellite, seal, SMARTag, spurred, square, stable, stage, stay, streamline, strive, TF, TKI, Today, twelve, undermine, underway, unfriendly, unmet, verified, Vicki, voluntary, War, withdrew

Removed: abiraterone, absence, acetate, adjusted, administered, advent, alia, began, beneficiary, biologic, bring, Bristol, closing, Codification, collaborator, commencement, commercializing, comparator, confidence, construction, County, critically, Darmstadt, derivative, distancing, doubling, economy, enzalutamide, essential, Europe, exacerbated, exist, fact, FASB, field, hedging, hospital, incorporate, IND, Informed, infusion, instituted, interrupt, interrupted, investigational, lacking, launch, limiting, measure, method, modestly, movement, NaN, objective, ORR, package, percent, phishing, placebo, population, predicted, prevented, proactive, producing, productivity, promotional, pursued, radiographic, rationale, Reauthorization, remote, remotely, removing, represent, reversed, role, SAFEbodyTM, shelter, sizable, social, soft, sourcing, statistically, strong, substance, supplementing, suspension, tested, travel, ultimate, unemployment, uptake, vaccinated, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EXEL transcripts

EXEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the “Company”), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended April 1, 2022, to which this Certification is attached as Exhibit 32.1 (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 10th day of May 2022.

/S/ Michael M. Morrissey, Ph.D.

/S/ Christopher J. Senner

Michael M. Morrissey, Ph.D.

Christopher J. Senner

President and Chief Executive Officer
(Principal Executive Officer)

Executive Vice President and Chief Financial Officer
(Principal Financial Officer)